Leona Bio

Leona Bio is a preclinical-stage biotechnology company dedicated to developing transformative therapies for neurodegenerative diseases, with a primary focus on frontotemporal dementia (FTD) caused by progranulin (PGRN) deficiency. The company leverages research into the regulation of progranulin levels and its lysosomal functions to identify novel therapeutic targets. Their lead programs aim to restore progranulin levels through various mechanisms, including targeting the sortilin-mediated degradation pathway. By addressing the underlying genetic and biochemical drivers of neurodegeneration, Leona Bio seeks to provide disease-modifying treatments for patients with limited options.